CEOs weigh in on biotechs going public earlier and earlier by Amirah Al Idrus Wednesday, June 12, 2019 CEOs weigh in on increasingly large biotech IPOs and an increase in companies going public at earlier stages.
BIO: In conversation with Emil Kakkis, Ultragenyx CEO by Amirah Al Idrus Friday, June 7, 2019 Nine years later after Emil Kakkis started Ultragenyx, he reflects on how he’s preserved the culture of a small biotech even as it expands beyond 700.
8. Crysvita by Amirah Al Idrus Crysvita is the first FDA-approved drug for XLH, a rare, inherited form of rickets.
Ultragenyx dumps CNS disorder program after phase 3 flop by Amirah Al Idrus Friday, October 26, 2018 Ultragenyx is abandoning its glucose transporter type-1 deficiency syndrome program after its drug UX007 missed its endpoints in a phase 3 trial.
David Thompson leaves Azure to join startup Inozyme by Conor Hale Tuesday, May 1, 2018 David Thompson has left Azure Biotech to join Inozyme Pharma as chief scientific officer as the company transitions to the clinical stage.
Chutes & Ladders—Bob Hugin retires as Celgene's executive chair by Angus Liu Friday, February 2, 2018 Bob Hugin retires from Celgene, Voyager founder steps down as CEO, Boehringer named new U.S. chief to replace retiring Fonteyne.
Ultragenyx up on XLH drug's phase 3 success by Amirah Al Idrus Monday, December 4, 2017 Ultragenyx Pharmaceuticals chalked up another win for its rare bone disease drug, burosumab, keeping it on track for a U.S. regulatory filing.
RNA biotech Arcturus backs onto Nasdaq in Alcobra deal by Nick Paul Taylor Thursday, September 28, 2017 The deal will give Arcturus a route to public investors at a time when interest in RNA drugs is flying high on the back of Alnylam’s phase 3 success.
Bruised Ultragenyx attempts swoop for in-demand Dimension by Ben Adams Monday, September 18, 2017 Ultragenyx is putting up $138 million in cash to wrestle gene therapy biotech Dimension away from its first suitor.
Phase 3 fail prompts Ultragenyx to can muscle disease drug by Nick Paul Taylor Wednesday, August 23, 2017 A GNE myopathy trial missed its primary endpoint and all key secondary endpoints, delivering a blow to Ultragenyx as it enters a critical period.
